Company intelligence / Profile preview

SciMar

Dauphin, Manitoba, Canadascimar.ca ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

SciMar has discovered a hormone called hepatalin (also known as hepatic insulin-sensitizing substance or HISS hormone) which they believe is the missing link in understanding type 2 diabetes. They are developing approaches to prevent, detect, and treat type 2 diabetes based on this discovery[1][4].

Therapeutic areas: Endocrinology
Industry: Biotech

Drug pipeline

2 assets

Hepatalin-S

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Non-profitsindustriesIndigenous communities[1]

Beyond the preview

Go deeper on SciMar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciMar.

Explore the full profile